Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron Corporation (Nasdaq: GERN) announced the grant of a non-statutory stock option for 80,000 shares of its common stock to a newly-hired employee. This option was issued on November 18, 2020, at an exercise price of $1.90 per share, matching the closing price on the grant date. The option has a 10-year term and vests over four years, beginning with a 12.5% vesting after six months and the rest in monthly installments. This action complies with Nasdaq Listing Rule 5635(c)(4) and pertains to Geron's 2018 Inducement Award Plan.
Geron Corporation (Nasdaq: GERN) announced that its CEO, John A. Scarlett, will present a company overview at the Stifel Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. ET. A live audio webcast of the presentation will be accessible on Geron’s website, with an archived version available for 30 days post-event. Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor for hematologic myeloid malignancies. For more details, visit www.geron.com.
Geron Corporation (Nasdaq: GERN) reported a net loss of $19.7 million for Q3 2020, slightly higher than the $15.2 million lost in Q3 2019. Revenue for the third quarter was $108,000, compared to $131,000 for the same period last year. The company continues to advance its imetelstat program, despite COVID-19 related challenges that may delay trial enrollment. Geron has approximately $274 million in cash, expected to support operations until the end of 2022, and plans to begin two Phase 3 trials in early 2021.
Geron Corporation (Nasdaq: GERN) announced that ten abstracts related to imetelstat, its telomerase inhibitor, are accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting scheduled online from December 5-8, 2020. The abstracts highlight data from Phase 2 trials supporting ongoing Phase 3 studies in lower risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). Notably, 42% of patients achieved red blood cell transfusion independence lasting over 20 months. The expected improvements in overall survival may mark significant advances in treating these conditions.
Geron Corporation (Nasdaq: GERN) will release its third quarter 2020 financial results on November 5, 2020, after market close. The results will be discussed in a conference call at 4:30 p.m. ET the same day. The press release will be available on the company’s website. A live webcast of the call will also be accessible, with archived options available for 30 days. Geron is focused on developing its telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies.
Geron Corporation (Nasdaq: GERN) announced the publication of positive data from the IMerge Phase 2 trial of imetelstat in the Journal of Clinical Oncology, highlighting its effectiveness for patients with lower risk myelodysplastic syndromes (MDS). The trial demonstrated a median transfusion independence duration of 21 months without new safety signals. These results support ongoing Phase 3 trials aimed at addressing anemia in MDS patients. The publication indicates increasing interest from the oncology community, enhancing the potential for future regulatory approval.
Geron Corporation (NASDAQ: GERN) announced a loan facility of up to $75 million with Hercules Capital and Silicon Valley Bank to support its development program for imetelstat. The financing provides non-dilutive resources for working capital and advancing two Phase 3 clinical trials: the ongoing IMerge trial for lower risk myelodysplastic syndromes and a planned trial for refractory myelofibrosis. The loan is structured in three tranches, with $25 million disbursed initially, and additional amounts contingent on achieving clinical milestones.
Geron Corporation (Nasdaq: GERN) announced a positive opinion from the EMA for its orphan drug designation of imetelstat for treating myelodysplastic syndromes (MDS). This designation could provide a 10-year marketing exclusivity in the EU post-approval. The ongoing IMerge Phase 3 clinical trial is set to enroll about 170 patients, with completion expected by Q1 2021 and results in H2 2022. Imetelstat has also received orphan drug status from the U.S. FDA. The company anticipates final approval by the European Commission by the end of July 2020.
Geron Corporation (NASDAQ: GERN) reported encouraging results from the IMerge Phase 2 clinical trial, showing a durable transfusion independence (TI) rate of 29% over one year for patients with lower risk myelodysplastic syndromes (MDS). The median duration of TI reached 20 months, and a 42% 8-week TI rate was noted. Additionally, analyses from the IMbark Phase 2 trial indicated potential improvements in overall survival and clinical benefits in patients with high-risk myelofibrosis. Ongoing Phase 3 trials aim to further evaluate imetelstat's efficacy.
Geron Corporation (Nasdaq: GERN) reported its Q1 2020 financial results, posting a net loss of $16.4 million, or $0.08 per share, compared to $10.1 million, or $0.05 per share, in Q1 2019. Revenues decreased slightly to $52,000 from $57,000. Operating expenses rose to $16.9 million, with R&D expenses increasing to $10.8 million due to higher clinical development costs. As of March 31, 2020, Geron held $133 million in cash and securities, bolstered by a recent $140 million public offering, providing operational funds into 2022. Revised guidance indicates a 2020 operating expense burn of $70 to $75 million due to COVID-19 measures.